Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationFull interpretation, no resequencing
Decipher
Hold a comprehensive report from another laboratory? We extract its full value and return a signed decision.
No new sample, no new sequencing
Pure interpretation
If you hold a comprehensive genomic report from another laboratory, Decipher extracts its full value and returns a signed Blueprint Care decision.
What we need
Your existing report, and ideally the underlying data file.
Plus your history
Relevant clinical context, so the reading is grounded in your situation.
What we do with it
The engine re-annotates every alteration against current knowledge, matches biomarkers to drugs and trials, and applies all six intelligence layers. KPCIRC’s molecular tumour board then authors and signs the plan.
You receive a complete report and regional-language summary, plus navigator support. The depth matches a fresh-test report, provided your existing data is comprehensive enough. We check that first.
Being clear about our limits
What we do and do not do
What we DO
- Re-annotate every alteration against current knowledge
- Apply all six intelligence layers and match trials, biosimilars and access
- Return a complete, tumour-board-signed decision
- Tell you honestly when your data is not complete enough
What we DON’T do
- Diagnose or decide treatment on its own
- Interpret markers your original report never measured
- Present an incomplete picture as complete
- Guarantee drug availability, approval, cover or benefit
Plain-language glossary (4 terms)
| Term | What it means |
|---|---|
| Interpretation | Turning an existing variant list into a ranked, evidenced decision. |
| Top-up | A small, targeted test to fill one missing marker such as TMB, MSI or PGx. |
| MTB | Molecular tumour board, the licensed panel that signs the final decision. |
| VUS | Variant of uncertain significance, a change whose meaning is not yet clear. |
Important information and regulatory status
Decipher and Decipher Plus is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal